CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Tofacitinib Administrationdrug
Likely dose
Tofacitinib Administration 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02197455
NCT02197455Phase 2Completed
CompareCT.gov

Tofacitnib for the Treatment of Alopecia Areata and Variants

Yale University·interventional·Posted Jul 22, 2014·Updated Apr 4, 2017

In Brief

A Phase 2 clinical trial evaluating Tofacitinib Administration for Alopecia Areata (AA) and 2 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata (AA), Alopecia Totalis (AT), Alopecia Universalis (AU)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 22, 2014
Enrollment StartJul 1, 2014
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.9 years ago

Interventions

Tofacitinib Administrationdrug

5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.